Research Paper Volume 13, Issue 12 pp 16248—16266

Pan-cancer analysis reveals an immunological role and prognostic potential of PXN in human cancer

PXN gene expression in different tumors and pathological stages (A) using TIMER2 to analyze the expression of PXN in different cancers or specific cancer subtypes (*P **P ***P B) using the box plot data to analyze the type of lymphoid neoplasm DLBC, LGG, thymoma, and uterine carcinosarcoma in TCGA, for which the corresponding normal tissues of the GTEx database were included as controls (**P C) Using the CPTAC dataset, PXN total protein expression levels in normal tissue versus primary tissue were analyzed for RCC, lung adenocarcinoma, breast cancer, UCEC, and colon cancer (***P D) Using TCGA data, PXN gene expression was analyzed by main pathological stage (stage I, stage II, stage III, and stage IV) of LIHC and BRCA. Log2 (TPM + 1) was used for the log scale.

Figure 1. PXN gene expression in different tumors and pathological stages (A) using TIMER2 to analyze the expression of PXN in different cancers or specific cancer subtypes (*P < 0.05; **P < 0.01; ***P < 0.001); and (B) using the box plot data to analyze the type of lymphoid neoplasm DLBC, LGG, thymoma, and uterine carcinosarcoma in TCGA, for which the corresponding normal tissues of the GTEx database were included as controls (**P < 0.01). (C) Using the CPTAC dataset, PXN total protein expression levels in normal tissue versus primary tissue were analyzed for RCC, lung adenocarcinoma, breast cancer, UCEC, and colon cancer (***P < 0.001). (D) Using TCGA data, PXN gene expression was analyzed by main pathological stage (stage I, stage II, stage III, and stage IV) of LIHC and BRCA. Log2 (TPM + 1) was used for the log scale.